


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**“COLESEVELAM HYDROCHLORIDE TABLETS” OBTAINED**  
**ANDA APPROVAL**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “Colesevelam Hydrochloride Tablets”, a blood lipid-lowering drug developed by the Group, has obtained approval of abbreviated new drug application (“**ANDA**”, i.e. United States generic drug application) from the United States Food and Drug Administration (“**FDA**”). Colesevelam hydrochloride tablets are a non-absorbable polymeric oral drug used alone or in combination with any statin as an adjunct to diet and exercise for the treatment of primary hyperlipidaemia to reduce the patient’s elevated low-density lipoprotein cholesterol (“**LDL-C**”) levels. It is also used as an adjunct to diet and exercise control to improve glycaemic control in adults with type 2 diabetes.

Colesevelam hydrochloride is the latest generation of bile acid sequestrant. The drug binds bile acids and hepatic bile acids, the main component of bile acids, in the intestine, thus preventing the reabsorption of bile acids. The heavy depletion of bile acids facilitates the conversion of cholesterol into bile acids. This compensation effect increases the clearance of LDL-C from the blood, which in turn reduces serum LDL-C levels.

The approval of this product in the United States will strengthen the Group's product portfolio in overseas and international markets and bring better treatment options to patients with high blood lipid levels.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 15 March 2022

*As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*